本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据上海证券交易所《上海证券交易所科创板上市公司自律监管指引第1 号——规范运作》的规定，现将安徽华恒生物科技股份有限公司（以下简称 "本公司"或"公司"）2025年半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 证券代码:688639 证券简称:华恒生物 公告编号:2025-033 安徽华恒生物科技股份有限公司 专项报告 （一）2021年首次公开发行股票募集资金情况 经中国证券监督管理委员会《关于同意安徽华恒生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]923号文）核准，公司于2021年 应募集资金总额为人民币62,532.00万元，根据有关规定扣除发行费用6,606.12万 元后，实际募集资金金额为55,925.88万元。该募集资金已于2021年4月到账。上 述资金到账情况业经容诚会计师事务所（特殊普通合伙）容诚验字 [2021]230Z0072号《验资报告》验证。公司对募集资金采取了专户存储管理。 截至2025年6月30日，公 ...

Core Viewpoint - The article discusses an innovative method for chemically recycling mixed plastic waste into valuable chemical products, addressing the environmental challenges posed by plastic waste [2][3]. Group 1: Research Overview - The research, published in Nature, presents a strategy to convert eight common types of plastic waste into their original chemical components or other valuable compounds [3][10]. - The method focuses on identifying functional groups in mixed plastic waste to facilitate the separation and conversion of these materials into useful products [5][8]. Group 2: Methodology - The research team developed a solid-state NMR method to accurately identify the types of plastics present in the mixed waste, which is crucial for the subsequent processing steps [5][6]. - By using selective solvents, the team was able to dissolve and separate specific plastics from the mixed waste, followed by catalytic processes to convert these plastics into valuable products [6][7]. Group 3: Results and Innovations - The study successfully demonstrated the feasibility of the proposed strategy using a real-life plastic mixture, yielding various chemical substances such as benzoic acid, plasticizers, and hydrocarbons [7][8]. - The key innovation lies in the universal strategy designed to tackle the challenge of chemical recycling of mixed plastics, allowing for adjustments in chemical steps based on the initial identification of major components [8][10].

Core Points - The U.S. is pressuring China to lift restrictions on rare earth exports, revealing its anxiety over the trade situation [1][3] - China's rare earth exports fell by 34% in May, with significant impacts on military-grade materials [3][5] - The U.S. faces a long and costly process to rebuild its rare earth supply chain, estimated to take 8-10 years and require hundreds of billions of dollars [5] - The trade war is reshaping global supply chains, with China transitioning from a reactive stance to a rule-setting position [3][5] - The U.S. is experiencing a dual challenge of needing to constrain China while simultaneously relying on its resources [5][9] Group 1: U.S.-China Trade Negotiations - The U.S. delegation, including key economic officials, is demanding China restore rare earth exports to April levels [1] - There is a disconnect in the negotiations, with the U.S. pushing for concessions while China calls for the removal of recent export restrictions [5][9] - The U.S. has violated previous agreements, such as the Geneva consensus, which has weakened the economic relationship [7] Group 2: China's Strategic Position - China holds significant leverage in the rare earth market, controlling 92% of refining and 99% of heavy rare earth processing [3] - The country is also advancing in other strategic sectors like renewable materials and biotechnology, further enhancing its bargaining power [5][9] - China's customs data shows a sharp decline in graphite electrode exports to the U.S., critical for the American steel industry [7] Group 3: Economic Implications - A complete decoupling of U.S.-China technology could lead to a global GDP decline of $1.5 trillion, equivalent to the entire economy of Australia [7] - The ongoing trade tensions are detrimental to both nations, with the U.S. potentially facing greater losses if it continues its current approach [9]

Core Viewpoint - Synthetic biology is a multidisciplinary field that integrates biology, informatics, genomics, and chemistry to design and construct artificial biological systems, marking a significant leap from understanding life to designing it, often referred to as the third biotechnology revolution [7][11]. Summary by Sections Synthetic Biology Overview - Synthetic biology involves the engineering of biological systems to produce valuable products through modified chassis cells that express specific genes to obtain target products [7][9]. - The core principles of synthetic biology include standardization, decoupling, and modularization, which facilitate the design and construction of biological systems [8][9]. Market Growth and Trends - The global synthetic biology market is projected to grow at a CAGR of 24%, reaching approximately $18.885 billion by 2024 [16][19]. - The healthcare sector is expected to be the largest segment, with a market size of $5.022 billion by 2024, accounting for 26.6% of the overall market [19]. Technological Advancements - Advances in gene sequencing, editing, and synthesis technologies have significantly reduced costs and barriers to entry in synthetic biology, enabling rapid development and iteration of engineered organisms [39][40]. - The integration of AI and big data in molecular design is accelerating the development of synthetic biology applications [39]. Applications and Benefits - Synthetic biology can replace traditional chemical synthesis or natural extraction methods, improving production economics and environmental sustainability [29][33]. - The technology allows for the production of a wide range of products, including pharmaceuticals, chemicals, and biofuels, using renewable resources and reducing reliance on fossil fuels [35][36]. Investment and Policy Support - There has been a surge in investment in synthetic biology, with global financing reaching $18 billion in 2021, nearly doubling from previous years [44]. - Governments in the U.S. and China are prioritizing synthetic biology in their strategic plans, recognizing its potential for innovation and economic growth [42][43].